Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ROIV Stock Forecast 2026-2027
$36.09
Current Price
$25.96B
Market Cap
Buy 12
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ROIV Price Targets
+24.7%
To High Target of $45.00
+10.8%
To Median Target of $40.00
-12.7%
To Low Target of $31.50
ROIV Price Momentum
+2.7%
1 Week Change
+24.2%
1 Month Change
+221.7%
1 Year Change
+66.3%
Year-to-Date Change
-1.5%
From 52W High of $36.63
+237.1%
From 52W Low of $10.71
📊 TOP ANALYST CALLS
Did ROIV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Roivant is one of their latest high-conviction picks.
Latest ROIV Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ROIV has a bullish consensus with a median price target of $40.00 (ranging from $31.50 to $45.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $36.09, the median forecast implies a 10.8% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ROIV Analyst Ratings
12
Buy
1
Hold
0
Sell
ROIV Price Target Range
Low
$31.50
Average
$40.00
High
$45.00
Current: $36.09
Latest ROIV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ROIV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 26, 2026 | Guggenheim | Yatin Suneja | Buy | Maintains | $36.00 |
| May 21, 2026 | Citigroup | Samantha Semenkow | Buy | Maintains | $42.00 |
| May 21, 2026 | TD Cowen | Yaron Werber | Buy | Maintains | $41.00 |
| May 21, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $34.00 |
| Apr 16, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 10, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 9, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Dec 15, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Dec 15, 2025 | Goldman Sachs | Buy | Maintains | $N/A | |
| Dec 12, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 11, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Oct 29, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Sep 18, 2025 | Goldman Sachs | Buy | Maintains | $N/A | |
| Sep 18, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Sep 18, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Sep 18, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Sep 18, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Sep 18, 2025 | B of A Securities | Neutral | Maintains | $N/A |
Roivant Sciences Ltd (ROIV) Competitors
The following stocks are similar to Roivant based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Roivant Sciences Ltd (ROIV) Financial Data
Roivant Sciences Ltd has a market capitalization of $25.96B with a P/E ratio of 1.9x. The company generates $8.26M in trailing twelve-month revenue with a 84.4% profit margin.
Revenue growth is -66.7% quarter-over-quarter, while maintaining an operating margin of -14,675.1% and return on equity of -7.6%.
Valuation Metrics
Market Cap
$25.96B
Enterprise Value
$22.04B
P/E Ratio
1.9x
PEG Ratio
0.0x
Price/Sales
3,161.8x
Growth & Margins
Revenue Growth (YoY)
-66.7%
Gross Margin
+87.3%
Operating Margin
-14,675.1%
Net Margin
+84.4%
EPS Growth
-66.7%
Financial Health
Cash/Price Ratio
+16.5%
Current Ratio
18.4x
Debt/Equity
2.0x
ROE
-7.6%
ROA
-14.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Roivant Sciences Ltd (ROIV) Business Model
About Roivant Sciences Ltd
What They Do
Develops innovative medicines and technologies.
Business Model
The company operates by creating specialized subsidiaries, known as Vants, that each focus on specific therapeutic areas. These Vants not only develop and commercialize drugs but also leverage technology to expedite drug discovery and enhance operational efficiency, generating revenue through the successful launch and sale of their therapeutic products.
Additional Information
Roivant Sciences maintains a diverse pipeline of investigational drugs across various therapeutic areas such as immunology and dermatology. Notable subsidiaries include Immunovant, Priovant, and Pulmovant, which address specific health conditions. Founded in 2014 and headquartered in New York City, the company also has offices in Boston and Basel.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
750
CEO
Mr. Matthew Gline
Country
United Kingdom
IPO Year
2020
Website
roivant.comRoivant Sciences Ltd (ROIV) Latest News & Analysis
Latest News
Quick Summary
Roivant Sciences plans three commercial launches, primarily featuring brepocitinib. The stock is considered expensive despite optimistic revenue projections for 2031.
Why It Matters
Roivant's upcoming product launches could drive significant revenue growth, but high current valuations may pose risks if projections aren't met, influencing investment decisions.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Roivant Sciences Ltd. (ROIV) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, discussing its strategic initiatives and future outlook.
Why It Matters
Roivant's presentation at a major healthcare conference signals potential investor interest and insight into its strategy, innovations, and market positioning, which can impact stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Roivant Sciences Ltd. (ROIV) presented at the Jefferies Global Healthcare Conference, discussing its strategies and developments in the healthcare sector.
Why It Matters
Roivant's presentation at a major healthcare conference signals potential developments and insights into its pipeline, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
1 month ago
Quick Summary
Roivant Sciences Ltd. (ROIV) presented at the Bernstein 42nd Annual Strategic Decisions Conference, discussing its strategic direction and initiatives.
Why It Matters
Roivant's presentation at a major conference could signal strategic developments or partnerships, influencing investor sentiment and potential stock movement.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Roivant (ROIV) is rated a Buy, with strong Phase 2 results for Immunovant's IMVT-1402 in rheumatoid arthritis. The company has $4.3 billion in cash and a clear path to profitability.
Why It Matters
Roivant's strong Phase 2 results for IMVT-1402 and its solid cash position suggest potential growth and profitability, making it an attractive investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Roivant Sciences Q4 Earnings Call Highlights
1 month ago
Quick Summary
Roivant Sciences (NASDAQ: ROIV) reported new data for IMVT-1402 in rheumatoid arthritis, upcoming results for mosliciguat in pulmonary hypertension, and is preparing for a potential brepocitinib launch.
Why It Matters
New data on IMVT-1402 and mosliciguat could indicate potential for strong market performance and revenue growth, while brepocitinib's launch readiness signals strategic advancement in treatments.
Source: MarketBeat
Market Sentiment:
Neutral
Frequently Asked Questions About ROIV Stock
What is Roivant Sciences Ltd's (ROIV) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Roivant Sciences Ltd (ROIV) has a median price target of $40.00. The highest price target is $45.00 and the lowest is $31.50.
Is ROIV stock a good investment in 2027?
According to current analyst ratings, ROIV has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $36.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ROIV stock?
Wall Street analysts predict ROIV stock could reach $40.00 in the next 12 months. This represents a 10.8% increase from the current price of $36.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Roivant Sciences Ltd's business model?
The company operates by creating specialized subsidiaries, known as Vants, that each focus on specific therapeutic areas. These Vants not only develop and commercialize drugs but also leverage technology to expedite drug discovery and enhance operational efficiency, generating revenue through the successful launch and sale of their therapeutic products.
What is the highest forecasted price for ROIV Roivant Sciences Ltd?
The highest price target for ROIV is $45.00 from at , which represents a 24.7% increase from the current price of $36.09.
What is the lowest forecasted price for ROIV Roivant Sciences Ltd?
The lowest price target for ROIV is $31.50 from at , which represents a -12.7% decrease from the current price of $36.09.
What is the overall ROIV consensus from analysts for Roivant Sciences Ltd?
The overall analyst consensus for ROIV is bullish. Out of 5 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $40.00.
How accurate are ROIV stock price projections?
Stock price projections, including those for Roivant Sciences Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 3:43 AM UTC